Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025
Humacyte reported Q3 revenue of $753,000, with $703,000 from Symvess sales, and a net loss of $17.5 million (GAAP EPS −$0.11). The company said 25 Value Analysis Committee approvals now cover 92 U.S. hospitals, with 16 hospitals ordering Symvess. Positive two-year Phase 3 dialysis trial results were presented, and an IND was submitted for a coronary bypass graft study in 2026.
